When it comes to recipes, I have a few nonnegotiables: simple, healthy and delicious! These creations are terrific for when you’re craving a quick breakfast or scrumptious afternoon snack: my ...

Axsome Therapeutics has entered into a settlement agreement with Hikma resolving patent litigation related to Axsome’s product Sunosi (solriamfetol). The litigation, which is pending in the ...

An icon of 3 horizontal dots. An icon of a paper envelope. An icon of a facebook f logo. An icon of a digital camera. An icon of a house. An icon of the Instagram logo. An icon of the LinkedIn logo.

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi (solriamfetol). The settlement ...

The agreement grants Hikma the right to market a generic version of Sunosi in the United States starting on or after September 1, 2040, if pediatric exclusivity is granted, or from March 1, 2040, ...

Under the terms of the settlement agreement, Axsome will grant Hikma a license to sell its generic version of Sunosi beginning on or after September 1, 2040, if pediatric exclusivity is granted ...

(RTTNews) - Axsome Therapeutics (AXSM) has entered into a settlement agreement with Hikma Pharmaceuticals USA, Inc. resolving patent litigation related to Axsomes product Sunosi or solriamfetol.

Under the terms of the settlement agreement, Axsome will grant Hikma a license to sell its generic version of Sunosi beginning on or after September 1, 2040, if pediatric exclusivity is granted ...